SeaStar Medical Holding Corporation filings document a medical-device issuer with common stock and publicly listed warrants, registration activity, governance matters, and material events. Securities Act registration statements describe delayed or continuous securities offerings and related capital-structure disclosures, while proxy materials cover annual-meeting voting procedures, board and governance matters, and compensation disclosures.
Current reports on Form 8-K record operating results, QUELIMMUNE and SCD business updates furnished with earnings releases, Nasdaq listing-compliance matters, officer appointments and compensation arrangements, and completed litigation-status disclosures. The filings also frame disclosure topics tied to QUELIMMUNE commercialization, SCD clinical development, FDA post-approval obligations, risk factors, and financing activity.
SeaStar Medical Holding Corp. (Nasdaq: ICU) has filed a Rule 424(b)(5) prospectus supplement dated 10 July 2025 to pause its at-the-market (ATM) equity program with H.C. Wainwright. The existing prospectus, issued 2 April 2025, permitted sales of up to $7.433 million in common stock; the company has already sold $1.191 million, leaving $6.242 million available. Effective immediately, no additional shares will be issued under the current prospectus, limiting near-term dilution, although the underlying Offering Agreement remains valid and the company may resume sales after filing a new supplement. ICU shares last traded at $0.7151 on 9 July 2025. Investors should review the referenced risk factors for dilution, financing, and operational risks.
The Form 8-K discloses results of SeaStar Medical Holding Corporation’s July 3, 2025 virtual annual meeting. Shareholders elected Class III directors Eric Schlorff and Kenneth Van Heel to terms expiring in 2028. Four governance and financing proposals were also approved:
- Equity Incentive Plan expansion: the 2022 Omnibus Plan share pool rises from 570,457 to 2,070,457 post-reverse-split and the evergreen provision is removed (1.83 m for / 1.12 m against). The wider pool increases potential equity compensation by >260% and may dilute existing holders.
- Lincoln Park financing capacity: shareholders authorised future issuances that could lift Lincoln Park’s ownership above 19.99% (2.60 m for / 0.37 m against), providing at-the-market capital but also further dilution risk.
- Auditor ratification: WithumSmith+Brown, PC was ratified with 6.17 m votes for and minimal opposition, supporting audit continuity.
- Adjournment flexibility passed if future proxy solicitation is needed.
Overall, the meeting strengthens board continuity and secures flexible financing tools, but materially increases the authorised share count—signalling potential dilution that investors should monitor.
Director John Neuman of SeaStar Medical Holding Corporation (ICU) has increased his position in the company through a significant stock purchase on June 24, 2025. The insider acquired 40,000 shares of common stock at a weighted average price of $0.3599 per share, with individual transaction prices ranging from $0.359 to $0.36.
Following this transaction, Neuman's direct ownership has increased to 80,000 shares of the company's common stock. The purchase was reported via Form 4 filing on June 28, 2025, within the required reporting timeline for insider transactions.
Key transaction details:
- Transaction type: Direct purchase of common stock
- Total transaction value: Approximately $14,396
- Position: Director
- Ownership type: Direct ownership
SeaStar Medical Holding Corporation (Nasdaq: ICU) has filed a Rule 424(b)(4) prospectus for a mixed securities offering designed to raise up to $4.0 million in gross proceeds. The company will sell 4,935,385 shares of common stock at $0.65 per share and 1,218,462 pre-funded warrants at $0.6499 each. Every share or pre-funded warrant is bundled with one Series A warrant (5-year term) and one Series B warrant (18-month term), both carrying a $0.65 exercise price. In addition, placement agent H.C. Wainwright will receive 430,769 warrants (exercise price = 125% of the offering price) plus cash fees equal to 7% of gross proceeds, a 1% management fee, and up to $125,950 in expenses.
The structure is best-efforts and has no minimum, meaning funds are immediately available to the company and investors will not receive refunds if demand is weak. Net proceeds before offering expenses are estimated at $3.68 million; actual proceeds may be substantially lower because warrant exercises are not included. The warrants and pre-funded warrants will not be listed, limiting secondary-market liquidity.
SeaStar is both an emerging growth and smaller reporting company. Following a 1-for-25 reverse split effected on 7 June 2024, ICU shares last closed at $0.9763, while listed $11.50 warrants traded at $0.0284. The company remains under a Nasdaq panel exception that expires 22 June 2025; by that date it must regain compliance with the $2.5 million stockholders’ equity rule and update Nasdaq on fundraising and 12-month projections. Failure could result in delisting.
Prospective investors should review the extensive Risk Factors section, which highlights dilution, delisting risk, and the absence of an escrow arrangement.
SeaStar Medical Holding Corp (ICU) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission, confirming that the company’s Form S-1 registration statement (File No. 333-288065) became effective on June 20 2025 at 12:00 p.m. ET. The effectiveness marks the final regulatory step required before the company may use the registration statement for activities described therein, such as issuing or reselling securities. No additional financial metrics, transaction details, or offering terms were included in this notice.